Advertisement

Immunsuppressive Therapie der multiplen Sklerose: Pro und Contra

  • U. Patzold
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für Neurologie book series (VDGNEUROLOGIE, volume 6)

Zusammenfassung

Seit über zwei Jahrzehnten wird immer wieder tiber Nutzen ünd Gefahren der Immunsuppression (IS) bei der multiplen Sklerose (MS) leidenschaftlich diskutiert. Wegen der methodischen Schwierigkeiten von Therapiestudien bei dieser Krankheit wurde die Diskussion zunächst über viele Jahre ausgetragen, ohne daß fundierte Kenntnisse über die Wirkung der IS vorlagen. Nun haben wir aber genügend Erfahrungen mit den unterschiedlichsten Methoden der IS. Es ist Zeit, Bilanz zu Ziehen, Nebenwirkungen und Wirkungen gegenüberzustellen und zu fragen: wie soil es eigentlich weitergehen?

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Allegretto M, Nicklas JA et al (1990) T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247:718–721CrossRefGoogle Scholar
  2. 2.
    Baker GL, Kahl LE et al (1987) Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Am J Med 83:1–9PubMedCrossRefGoogle Scholar
  3. 3.
    Carter JL, Hafler DA et al (1988) Immunosuppression with high–dose i. v. cyclosphosphamide and ACTH in progressive multiple sclerosis: cumulative 6–year experience in 164 patients. Neurology 38 (Suppl 2):9–14PubMedGoogle Scholar
  4. 4.
    Cockbum IT, Krupp P (1989) The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun 2:723–731CrossRefGoogle Scholar
  5. 5.
    Double–masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group (1988) Lancet 2:179–183Google Scholar
  6. 6.
    Ellison GW, Myers LW et al (1989) A placebo–controlled, randomized, double–masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 39:1018–1026PubMedGoogle Scholar
  7. 7.
    Goodkin DE, Plencner S et al (1987) Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nommaintenance therapy. Arch Neurol 44:823–827PubMedCrossRefGoogle Scholar
  8. 8.
    Gonsette RE, Demonty L et al (1984) Immunosuppression with cyclophosphamide in multiple sclerosis. In: Gonsette RE, Delmotte P (Hrsg) Immunological and clinical aspects of multiple sclerosis. MTP Press, Lancaster: 126–134Google Scholar
  9. 9.
    Haas JF, Kittelmann B et al (1987) Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cander 55:213–218CrossRefGoogle Scholar
  10. 10.
    Hauser SL, Dawson DM et al (1983) Intensive immunsuppression in progressive multiple sclerosis. A randomized, three-arm study of highdose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 308:173–180PubMedCrossRefGoogle Scholar
  11. 11.
    Hohlfeld R, Michels M et al (1988) Azathioprine toxicity during long–term immunosuppression of generalized myasthenia gravis. Neurology 38:258–261PubMedGoogle Scholar
  12. 12.
    Hommes OR, Lamers KJB et al (1980) Effect of intensive immunosuppression on the course of chronic–progressive multiple sclerosis. J Neurol 223:177–190CrossRefGoogle Scholar
  13. 13.
    Kappos L, Patzold U et al (1988) Cyclosporine versus azathioprine in the long–term treatment of multiple sclerosis–results of the German multicenter study. Ann Neurol 23:56–63PubMedCrossRefGoogle Scholar
  14. 14.
    Lhermitte F, Marteau R et al (1984) Traitement prolongé de la sclérose en plaques par l’azathioprine a doses moyennes. Bilance de quinze années d’experience. Rev Neurol (Paris) 140:553–558Google Scholar
  15. 15.
    Mankin J, Hudson WH et al (1989) A parametric analysis of the hazard of cancer after transplantation. Transplant Proc 21:3201–3204PubMedGoogle Scholar
  16. 16.
    Myers LW, Fahey JL et al (1987) Cyclophosphamide pulses in chronic progressive multiple sclerosis. A preliminary clinical trial. Arch Neurol 44:828–832PubMedCrossRefGoogle Scholar
  17. 17.
    Oksenberg JR, Stuart S et al (1990) Limited heterogeneity of rearranged T–cell receptor V alpha transcripts in brains of multiple sclerosis patients. Nature 345:344–346PubMedCrossRefGoogle Scholar
  18. 18.
    Patzold U (1985) Multiple Sklerose-Verlauf und Therapie. Thieme, Stuttgart New YorkGoogle Scholar
  19. 19.
    Pedersen-Bjergaard J, Larsen SO et al (1987) Risk of therapy-related leukaemia and preleukaemia after Hodgkins disease. Lancet 11:83–88CrossRefGoogle Scholar
  20. 20.
    Pedersen–Bjergaard J, Ersboll J et al (1988) Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkins lymphoma. N Engl J Med: 1028–1032Google Scholar
  21. 21.
    Penn I (1987) Cancers following cyclosporine therapy. Transplant Proc:2211–2213Google Scholar
  22. 22.
    Penn I (1987) Neoplastic consequences of transplantation and chemotherapy. Cancer Detect Prev Suppl 1:149–157PubMedGoogle Scholar
  23. 23.
    Pitt PI, Sultan AH et al (1987) Association between azathioprine therapy and lymphoma in rheumatoid disease. JR Soc Med 80:428–429Google Scholar
  24. 24.
    Sheil AGR, Flavel S et al (1987) Cancer incidence in renal transplant patients treated with azathioprine or cyclosporine. Transplant Proc 19:2214–2216PubMedGoogle Scholar
  25. 25.
    Singh G, Fries JF et al (1989) Toxic effects of azathioprine in rheumatoid arthritis. A national post–marketing perspective. Arthritis Rheum 32:837–843PubMedCrossRefGoogle Scholar
  26. 26.
    Tage-Jensen U, Schlichting P et al (1987) Malignancies following long–term azathioprine treatment in chronic liver disease. A report from the Copenhagen Study Group for Liver Diseases. Liver 7:81–83PubMedGoogle Scholar
  27. 27.
    The Multiple Sclerosis Study Group (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double–blinded, placebo–controlled clinical trial. Ann Neurol 27:591–605CrossRefGoogle Scholar
  28. 28.
    Wucherpfennig KW, Ota K et al (1990) Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science 248:1016–1019PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • U. Patzold

There are no affiliations available

Personalised recommendations